With a strong pharmaceutical sector, an ageing population and a wealth of expertise, Japan is a fascinating drug discovery and development market. In our third installment of the Spotlight on Japan mini-series, Chris Hodgens, Real Estate Practice Group partner and industry specialist, Ryosuke Tateishi, Healthcare & Life Sciences Compliance and Regulatory Partner and Tsugihiro Okada, IP and Information Technology industry expert take a closer look at the drug development framework in Japan, including regulatory approval filing, clinical trial implementation and drug development collaboration.
Podden och tillhörande omslagsbild på den här sidan tillhör
Baker McKenzie. Innehållet i podden är skapat av Baker McKenzie och inte av,
eller tillsammans med, Poddtoppen.
